Covidien Acquires CV Ingenuity: Highlights Promise In Drug-Coated Balloons

Article preview from IN VIVO - January, 2013

In late December 2012, Covidien announced a definitive agreement to acquire drug-coated balloon company CV Ingenuity for an undisclosed amount. Covidien joins large cardiovascular device players such as Medtronic, which gained a drug-coated balloon when it acquired Invatec in 2010, and CR Bard, which has the lead in the US market as a result of its acquisition last year of Lutonix Inc. as well as a large number of DCB companies based in Europe.

 

Covidien Acquires CV Ingenuity: Highlights Promise In Drug-Coated Balloons

Article preview from IN VIVO - January, 2013

In late December 2012, Covidien PLC announced a definitive agreement to acquire stealthy Fremont, CA-based drug-coated balloon (DCB) company CV Ingenuity Corp., for an undisclosed amount. Covidien joins large cardiovascular device players Medtronic Inc., which gained a drug-coated balloon when it acquired Invatec SPA in 2010 and CR Bard Inc., which has the lead in the US market as a result of its acquisition last year of Lutonix Inc. as well as a large number of DCB companies based in Europe.

While much of the interventional cardiology market remained under pressure in 2012, drug-coated balloons attracted considerable interest at interventional meetings last year. These balloon angioplasty catheters, like drug-eluting stents, deliver anti-restenosis agents to the vessel wall, but do so without leaving behind a permanent implant that might cause problems later on. DCBs offer some intriguing possibilities for treating challenging cases where traditional balloon angioplasty and stenting have fallen short. Some of the most promising applications for DCBs in the peripheral vessels include the treatment of atherosclerotic disease in the difficult infrapopliteal and superficial femoral arteries of the lower leg, as well as treatment of blocked dialysis access grafts.

The potential applications for DCBs in the coronary space are less clear, since DES can effectively address most coronary cases; however, DCBs may open up new treatment options for coronary in-stent restenosis, small vessel disease, and bifurcation disease, all of which are problematic areas for existing stent technologies.

Continued...

Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.

Plus:

To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512